Eli Lilly and Company announced at this year's European Association for the Study of the Liver (EASL) annual meeting the positive results of the phase 2 clinical trial SYNERGY-NASH of its heavyweight GLP-1 drug, tirzepatide, for the treatment of metabolic dysfunction-related nonalcoholic steatohepatitis (NASH). The analysis showed that compared with placebo, 73.3% of patients treated with the highest dose of tirzepatide achieved improvement of MASH and no worsening of liver fibrosis, the primary endpoint, and more than half of the patients achieved significant improvement of liver fibrosis of ≥ grade 1.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.